D

David J. Kwiatkowski

Brigham and Women's Hospital

ORCID: 0000-0002-5668-5219

Publishes on Tuberous Sclerosis Complex Research, PI3K/AKT/mTOR signaling in cancer, Bladder and Urothelial Cancer Treatments. 1k papers and 80.6k citations.

PubIndex Score98Top 2%How it's scored

🌟#1 Current Senior Leader in Tuberous Sclerosis Complex Research 🌟#3 Current Senior Leader in Tumors and Oncological Cases

1kPublications

80.6kTotal Citations

#1in Tuberous Sclerosis Complex Research

First publication: 1986First senior author: 1991

Tuberous Sclerosis Complex Research PI3K/AKT/mTOR signaling in cancer Bladder and Urothelial Cancer Treatments Lung Cancer Treatments and Mutations Renal cell carcinoma treatment

Top publicationsby citations

The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

Caleb Davis, Christopher J. Ricketts, Min Wang et al.|Cancer Cell|2014

Cited by 860

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Pasi A. Jänne, Yuebi Hu et al.|JAMA Oncology|2018

Cited by 689

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Yiqun Zhang, Chad J. Creighton, Patrick Kwok‐Shing Ng et al.|Cancer Cell|2017

Cited by 656

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

Lynsey M. Meikle, David J. Kwiatkowski|Journal of Neuroscience|2008

Cited by 502

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

Hongbing Zhang, David J. Kwiatkowski|Journal of Clinical Investigation|2003

Cited by 479